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Cough is an essential neurally-mediated reflex that has evolved to protect the upper airways 
from obstruction, and to expel chemical and mechanical irritants. When heightened or 
persistent, however, cough presents a clinically-challenging source of considerable physical 
and psychological morbidity [1, 2]. In the US, cough continues to be the commonest single 
symptom for which patients seek a medical consultation [3]. Chronic cough, defined as cough 
continuing > 8 weeks, is also globally prevalent and accounts for 10% of respiratory referrals 
to secondary care [4].  
 
The associated societal and healthcare costs of cough are huge. Acute cough contributes to 
approximately 34.0 million working days lost each year in the UK through minor illnesses [5], 
with more than £100 million pounds being spent on over-the-counter antitussive drugs each 
year [6]. Despite meticulous, and often lengthy, diagnostic protocols, chronic cough remains 
unexplained or refractory in 12 – 42% of cases [7], following which patients are frequently 
subjected to sequential trials of anti-tussives with limited clinical efficacy and/or undesirable 
side-effects [8]. A recent internet-based survey, conducted across 29 different European 
countries, found that most subjects with chronic cough responded that their cough 
medication had limited or no effectiveness (57% and 36%, respectively), with only 7% 
reporting that medications they had tried for their cough were effective [2]. This lack of 
effective treatment reflects our limited understanding of the mechanistic basis of cough. 
Indeed, it is increasingly recognised that in order to effectively treat cough syndromes, there 
is a need to look beyond the presence (or not) of underlying disease processes, and towards 
a better understanding of physiological control of the cough reflex itself.  
 
This paradigm shift has heralded the recent description of the “cough hypersensitivity 
syndrome” (CHS) by a European Respiratory Society Taskforce. CHS is defined as a clinical 
entity characterised by cough as a major component, which is often triggered by low levels of 
thermal, mechanical, or chemical exposure [9]. The main mechanism of CHS has been 
suggested to be dysregulated sensory neural pathways and central processing in cough reflex 
regulation, as supported by a number of observations. Firstly, the symptom profile of CHS is 
similar to that of neuropathic disorders such as pain. CHS patients frequently report 
exaggerated coughing to known tussive stimuli, for example, strong odours and smoke 
(hypertussia) and to non-tussive stimuli such as talking and laughing (allotussia), and 
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abnormal sensations such as laryngeal paraesthesia (tickle) [10]. Secondly, neuropeptides, 
released from sensory nerves, can act as neurotransmitters and initiate local inflammatory 
responses and these are present in increased concentrations in the airways of patients with 
persistent cough [11, 12]. Central sensitisation to respiratory sensations, involving 
convergence of sensory bronchopulmonary C-fibres with low threshold Aδ-fibres onto second 
order neurons in the brainstem, is suggested by animal models of bronchopulmonary C-fibre 
activation leading to an increase in Aδ-mediated cough reflex sensitivity [13] [14]. Functional 
neuroimaging studies are beginning to provide insights into the neurobiology of chronic 
cough, including increased activation in the cortical and subcortical brain centres that 
integrate the intensity and location of the cough stimulus, and in regions previously 
implicated in voluntary cough suppression [15]. Centrally-acting neuromodulatory drugs such 
as gabapentin [16], amitriptyline [17]  and morphine [18], and speech and physiotherapy 
interventions [19, 20], are also effective in some patients. Direct evidence for neural 
dysfunction is however lacking because, except for peripheral lung tissues, human neural 
tissues are very difficult to obtain. Thus, at present, CHS is still a conceptual entity.  
 
The key regulator of CHS also remains elusive. Ion channels present on respiratory vagal 
afferent nerve termini can be activated by a wide variety of stimuli to elicit cough and other 
reflexes. The main family of ion channels implicated in the initiation of sensory reflexes are 
the transient receptor potential (TRP) channels, with most information pertinent to cough 
physiology having been gathered for transient receptor potential vanilloid (TRPV) 1, transient 
receptor potential ankyrin (TRPA) 1, TRPV4, and transient receptor potential melastatin 
(TRPM) 8 [21]. Capsaicin, the active ingredient of chilli pepper, binds TRPV1 receptors causing 
pain, burning sensation, cough and urge-to-cough, and is one of the most potent tussigens 
used in inhalation cough challenge tests [21]. TRPV1 is expressed by vagal afferent C- and Aδ-
nociceptive fibres innervating the airways [21] and TRPV1 receptor expression is increased in 
airway nerves of chronic cough patients [22]. However, despite efficacy being predicted in 
preclinical guinea pig and human in vitro vagal models [21], the potent TRPV1 receptor 
antagonist XEN-D0501 failed to significantly alter objective 24-hour cough frequency or 
subjective urge-to-cough in patients with refractory chronic cough in a recent clinical trial 
[23]. TRPA1 receptors are also present on vagal sensory afferents and bind a wide range of 
irritants (but not capsaicin) present in tussigenic environmental pollutants such as cigarette 
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smoke, as well as functioning as cold thermosensors [24]. However, despite the preclinical 
promise of TRPA1 receptors as effective anti-tussive targets [24], a TRPA1 antagonist did not 
show significant anti-tussive effects in humans (study completed in 2014 but unpublished) 
[25, 26]. Other examples where preclinical models of cough have failed to reliably translate 
to clinical efficacy are neurokinin (namely substance P) antagonists (reviewed in [27]), and 
the novel voltage-gated sodium channel blocker GSK2339345 [28].  
 
These findings are, however, in stark comparison to those of a recent randomised, controlled 
clinical trial of an antagonist of the purinergic P2X3 receptor (AF219/MK7264), which caused 
a dramatic decrease in cough frequency in patients with refractory chronic cough [29]. P2X3 
receptors are relatively specific for adenosine triphosphate (ATP), release of which is 
triggered by tissue inflammation and present in increased concentrations in the airways of 
chronic smokers and in COPD [30], after allergen challenge in asthmatics [31], and in fibrotic 
interstitial lung disease [32].  P2X3 and P2X2/3Rs are also present on the central projections 
of these neurons within the dorsal horn of the spinal cord and brainstem, where they are 
implicated in augmenting release of glutamate [33] and substance P [34], mediating central 
sensitisation at the first synapse. Animal studies implicate P2X3Rs in central sensitisation to 
pain including inflammatory hyperalgesia [35] and mechanical allodynia underlying bladder 
pain [36], and in arthritic and cancer pain [37] [38]. However, ATP administered to the 
bronchial tree does not cause a dramatic left-shift in cough reflex sensitivity [39]. Thus the 
P2X3 receptor may merely be a link in the chain of cough hypersensitivity rather than the 
primary mediator [25]. 
 
In this issue of the European Respiratory Journal, WORTLEY et al. [REF] report an elegant series 
of investigations in which they identify, for the first time, fatty acid amide hydrolase (FAAH) 
inhibition as a target for the development of novel, anti-tussive agents through modulation 
of the endocannabinoid system in preclinical guinea pig and human models. FAAH is an 
integral membrane protein found within the nervous system and is responsible for the 
hydrolysis of the endocannabinoid N-arachidonoyl ethanolamine (anandamide, AEA), and 
other related fatty acid amides (FAAs) such as palmitoylethanolamine (PEA), N-
oleoylethanolamide (OEA) and linoleoyl ethanolamide (LEA). The recent identification of 
cannabinoid (CB1 and CB2) receptors and their endogenous lipid ligands has triggered an 
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exponential growth of studies exploring the endocannabinoid system and its regulatory 
functions in health and disease. Modulating the activity of the endocannabinoid system holds 
therapeutic promise in a wide range of disparate diseases and pathological conditions [40], 
notably including neuropathic pain [41]. The G-protein coupled receptors CB1 are the “brain 
receptors” for cannabinoids in the mammals, but are also present at much lower 
concentrations in a variety of peripheral tissues and cells. A second cannabinoid G-protein 
coupled receptor (GPCR), CB2, is primarily expressed peripherally in cells of the immune and 
hematopoietic systems but have also been identified in the brain, in nonparenchymal cells of 
the cirrhotic liver, in the endocrine pancreas, and in bone [40]. Activation of the CB2 receptor 
subtype has previously been shown to inhibit both guinea-pig and human airway sensory 
nerve activity and the cough reflex in guinea-pigs [42], modulation of sensory nerve activity 
being shown to be elicited both by the exogenous ligands capsaicin and hypertonic saline and 
by endogenous modulators such as PGE2 and low pH stimuli [43]. Although non-selective 
cannabinoids, such as anandamide, have been shown to suppress the cough reflex [44, 45], 
the associated (predominantly CB1-mediated) side effects such as sedation, cognitive 
dysfunction, tachycardia and psychotropic effects have hampered the use of such agonists for 
treatment purposes [46]. This suggested that the development of CB2 agonists, devoid of 
CB1-mediated central effects, could provide a new and safe antitussive treatment for chronic 
cough without these undesirable central side-effects. 
 
Peripheral elevation of endocannabinoids provides an attractive alternative pharmacological 
strategy through which to indirectly target vagal afferent CB2 receptor activation. In a 
conscious guinea pig model, WORTLEY et al. [REF] demonstrate inhibition of citric acid (low pH) 
provoked cough in association with elevated FAAs, brought about by pharmacological 
inhibition of FAAH (FAAHi). This suggests FAAHi as a potential novel target for the 
pharmacotherapy of CHS. Then, in an isolated guinea-pig vagus nerve model, PEA is shown to 
cause a concentration related inhibition of both low pH- and capsaicin-induced 
depolarisation. WORTLEY et al. subsequently confirm this effect to be a CB2-, not CB1-, 
receptor-mediated mechanism, operating through activation of Ca2+-activated K+ (SKCa) 
channels. Remarkably, FAAHi-mediated inhibition of depolarisation is similarly demonstrated 
in a human vagal nerve preparation, again via a CB2-PP2A-SKCa channel mechanism. 
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We await in vivo human studies of FAAH inhibition in chronic cough with the optimism that, 
counter to what might otherwise be predicted from previous experience [27], direct 
translation of physiological mechanism from rodent to man will translate to clinical efficacy. 
Lack of efficacy and safety are of course major causes of attrition in the pharmaceutical 
industry, and the former is likely to be a more significant contributor to attrition in therapeutic 
areas in which animal models of efficacy are unpredictive [47]. The parallels here between 
CHS and neuropathic pain are ominous [48], and highlight the need for robust preclinical 
human models; a problem because access to human vagal nerve preparations is challenging. 
A call to improve translation through a better understanding of, and control for, differences 
in human and animal preclinical and cellular models [27], together with the need to reduce, 
replace and refine the use of animals for scientific purposes, brings an urgent requirement for 
development of novel in vitro models of cough hypersensitivity based on human biology.  
 
Could human sensory “peripheral neuronal equivalents” (PNEs), as introduced in this issue of 
the Journal by CLARKE et al., meet this challenge? Human dental pulp stem cells (hDPSCs) are 
of neural crest origin and as such have a propensity to differentiate towards a neuronal 
phenotype [49]. CLARKE et al., describe refinement of the hDPSC model to produce PNEs that 
have morphological, molecular and functional characteristics of sensory neurons. Moreover, 
these PNEs express functional TRPA1 and, intriguingly, exhibit TRPA1 channel hyper-
responsiveness following stimulation with both nerve growth factor (NGF) and the viral 
mimetic Poly(I:C). Of course, TRPA1 channel hyper-responsiveness is physiologically distinct 
to neuronal hypersensitivity, and further work is required to study the latter phenomenon in 
the PNE model. Confirmation that a similar functional relationship exists between TRPA1 and 
live respiratory viruses to that demonstrated using the viral mimetic Poly(I:C) in the PNE 
model would also add relevance to the field of clinical respiratory medicine. An additional, 
albeit unavoidable, limitation of any in vitro peripheral sensory model of cough, human or 
otherwise, is that it is impossible to predict how the resultant pattern of afferent activity will 
be processed in central brain pathways. Most current clinically-effective drugs are centrally-
acting [16, 18] and normalisation of cough frequency did not appear to be a prerequisite for 
clinical response to AF219/MK7264 [29]. This underlines the importance of understanding 
central pathways subserving cough perception in order to achieve antitussive effects.  
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These limitations should not, however, distract from the potential of the work of CLARKE et al. 
to provide a much-needed human in vitro model for the study of inflammatory TRP channel 
regulation and related CHS mechanisms. Such models should improve efficiency of translation 
to therapeutic development through larger-scale screening of pharmaceutical compounds on 
the basis of their functional interactions, improved drug dosage and frequency prediction 
before going to man, and a better understanding of interspecies differences. These could also 
prove helpful in improving the therapeutic ratio of drugs where the maximal clinical dose is 
limited by intolerable side-effect profiles [50]. The current level of interest in identifying 
antitussive targets and efficacy in preclinical models is reflected by the variety of alternate 
animal [51-54] and human cellular [55] options in development. These, together with 
identification of novel pharmacological targets [ref WORTLEY et al.], should provide 
opportunities to accelerate progress to positive first-in-man trials through a better 
understanding of the pathophysiology of human cough reflex hypersensitivity. 
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